[HTML][HTML] Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
Y Zhang, Y Wang, Y Liu, C Tong, C Wang, Y Guo, D Ti… - Leukemia, 2022 - nature.com
Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
Y Zhang, Y Wang, Y Liu, C Tong, C Wang, Y Guo, D Ti… - Leukemia, 2021 - europepmc.org
Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
[HTML][HTML] Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
Y Zhang, Y Wang, Y Liu, C Tong, C Wang, Y Guo, D Ti… - Leukemia, 2022 - ncbi.nlm.nih.gov
Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial
Y Zhang, Y Wang, Y Liu, C Tong, C Wang… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …